

Title (en)  
FORMULATION OF L-ORNITHINE PHENYLACETATE

Title (de)  
FORMULIERUNG VON L-ORNITHIN-PHENYLACETAT

Title (fr)  
FORMULATION DE PHÉNYLACÉTATE DE L-ORNITHINE

Publication  
**EP 3373923 A4 20190703 (EN)**

Application  
**EP 16865158 A 20161111**

Priority  
• US 201562255300 P 20151113  
• US 201662276754 P 20160108  
• US 201615133087 A 20160419  
• US 2016061678 W 20161111

Abstract (en)  
[origin: WO2017083758A1] Some embodiments of the present application are directed to oral formulations of L- ornithine phenylacetate and methods of using the same. These oral formulations offer alternative administration route than the standard intravenous administration of L-ornithine phenylacetate for treating hyperammonemia in patients having various acute and chronic liver diseases and disorders, for example, acute liver failure, liver cirrhosis, liver decompensation, portal hypertension, hepatic encephalopathy, or patients with urea cycle disorders.

IPC 8 full level  
**A61K 31/198** (2006.01); **A61K 31/192** (2006.01); **A61K 31/195** (2006.01); **A61P 1/16** (2006.01); **C07C 57/32** (2006.01)

CPC (source: CN EP IL KR)  
**A61K 9/0053** (2013.01 - CN KR); **A61K 9/0095** (2013.01 - KR); **A61K 9/5031** (2013.01 - IL); **A61K 9/5042** (2013.01 - IL); **A61K 9/5078** (2013.01 - EP IL); **A61K 31/192** (2013.01 - IL); **A61K 31/195** (2013.01 - IL); **A61K 31/198** (2013.01 - CN EP IL KR); **A61P 1/16** (2017.12 - CN EP KR); **A61P 3/00** (2017.12 - EP); **A61P 7/00** (2017.12 - CN EP); **A61P 9/00** (2017.12 - EP); **A61P 9/12** (2017.12 - CN); **A61P 13/00** (2017.12 - CN); **A61P 13/02** (2017.12 - EP); **A61P 25/00** (2017.12 - CN); **A61K 9/5031** (2013.01 - EP); **A61K 9/5042** (2013.01 - EP)

Citation (search report)  
• [X] WO 2010144498 A2 20101216 - UCL BUSINESS PLC [GB], et al  
• [X] WO 2006056794 A1 20060601 - UCL BIOMEDICA PLC [GB], et al  
• [I] VENTURA-COTS MERITXELL ET AL: "Safety of Ornithine Phenylacetate in Cirrhotic Decompensated Patients : An Open-label, Dose-escalating, Single-cohort Study", vol. 47, no. 10, 1 January 2013 (2013-01-01), pages 881 - 887, XP009507196, ISSN: 0192-0790, Retrieved from the Internet <URL:http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00004836-201311000-00013> DOI: 10.1097/MCG.0B013E318299C789  
• [I] JALAN R ET AL: "L-Ornithine phenylacetate (OP): A novel treatment for hyperammonemia and hepatic encephalopathy", MEDICAL HYPOTHESES, EDEN PRESS, PENRITH, US, vol. 69, no. 5, 27 April 2007 (2007-04-27), pages 1064 - 1069, XP029096478, ISSN: 0306-9877, DOI: 10.1016/J.MEHY.2006.12.061  
• [I] YTREBO LARS MARIUS ET AL: "L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure", HEPATOLOGY, JOHN WILEY & SONS, INC, US, vol. 50, no. 1, 1 July 2009 (2009-07-01), pages 165 - 174, XP009164051, ISSN: 0270-9139, [retrieved on 20090218], DOI: 10.1002/HEP.22917  
• [X] RUNE GANGSØY KRISTIANSEN ET AL: "L-Ornithine phenylacetate reduces ammonia in pigs with acute liver failure through phenylacetylglycine formation: a novel ammonia-lowering pathway", AMERICAN JOURNAL OF PHYSIOLOGY. GASTROINTESTINAL AND LIVER PHYSIOLOGY, 15 November 2014 (2014-11-15), United States, pages G1024 - G1031, XP055532599, Retrieved from the Internet <URL:https://www.physiology.org/doi/full/10.1152/ajpgi.00244.2014> DOI: 10.1152/ajpgi.00244.2014  
• [X] VAIRAPPAN BALASUBRAMANIAN ET AL: "Ammonia reduction with ornithine phenylacetate restores brain eNOS activity via the DDAH-ADMA pathway in bile duct-ligated cirrhotic rats", AMERICAN JOURNAL OF PHYSIOLOGY - GASTROINTESTINAL AND LIVER PHYSIOLOGY, vol. 302, no. 1, 1 January 2012 (2012-01-01), US, pages G145 - G152, XP055532625, ISSN: 0193-1857, DOI: 10.1152/ajpgi.00097.2011  
• See references of WO 2017083758A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**WO 2017083758 A1 20170518**; AU 2016353350 A1 20180510; AU 2016353350 B2 20210923; AU 2021290236 A1 20220210; BR 112018009349 A2 20181113; BR 112018009349 A8 20190226; CA 3004331 A1 20170518; CN 108366983 A 20180803; CN 113768863 A 20211210; EP 3373923 A1 20180919; EP 3373923 A4 20190703; IL 258630 A 20180628; IL 258630 B1 20230401; IL 258630 B2 20230801; JP 2018533601 A 20181115; JP 2022058446 A 20220412; JP 7294807 B2 20230620; KR 20180086431 A 20180731; MX 2018005088 A 20190516; MX 2022001517 A 20221116; RU 2018113801 A 20191216; SG 11201802987U A 20180530

DOCDB simple family (application)  
**US 2016061678 W 20161111**; AU 2016353350 A 20161111; AU 2021290236 A 20211221; BR 112018009349 A 20161111; CA 3004331 A 20161111; CN 201680066488 A 20161111; CN 20211062923 A 20161111; EP 16865158 A 20161111; IL 25863018 A 20180411; JP 2018524369 A 20161111; JP 2021213640 A 20211228; KR 20187016373 A 20161111; MX 2018005088 A 20161111; MX 2022001517 A 20180425; RU 2018113801 A 20161111; SG 11201802987U A 20161111